DDInter1592 DDInter462
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Rifapentine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Rifapentine {u} (Compound) upregulates {v} (Gene) AGL
AGL {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Rifapentine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Rifapentine {u} (Compound) upregulates {v} (Gene) AGL
AGL {u} (Gene) regulates {v} (Gene) NARFL
NARFL {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} (Compound) binds {v} (Gene) SLCO1B3
SLCO1B3 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Rifapentine {u} (Compound) upregulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is regulated by {v} (Gene) ATF3
ATF3 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
CYP3A7-CYP3A51P {u} (Gene) is bound by {v} (Compound) Nelfinavir
Nelfinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Rifapentine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Dabrafenib (Compound)
Rifapentine (Compound) upregulates AGL (Gene) and AGL (Gene) is upregulated by Dabrafenib (Compound)
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Rifapentine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Rifapentine (Compound) upregulates AGL (Gene) and AGL (Gene) regulates NARFL (Gene) and NARFL (Gene) is upregulated by Dabrafenib (Compound)
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin (Compound) binds SLCO1B3 (Gene) and SLCO1B3 (Gene) is bound by Dabrafenib (Compound)
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) resembles Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Rifapentine (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) is regulated by ATF3 (Gene) and ATF3 (Gene) is upregulated by Dabrafenib (Compound)
Rifapentine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Nelfinavir (Compound) and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)